{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:06:19Z","timestamp":1789545979816,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1801525N"],"award-info":[{"award-number":["1801525N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bonr.2026.101934","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:01:01Z","timestamp":1782144061000},"page":"101934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"30","author":[{"given":"G.","family":"Mammone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Coropciuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Van den Wyngaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kerkhofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Meerschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vissenaekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Beuselinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2026.101934_bb0005","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bonr.2026.101934_bb0010","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/oncolo\/oyac213","article-title":"Bone health and denosumab discontinuation in oncology populations","volume":"27","author":"Cheung","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bonr.2026.101934_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101934_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bonr.2026.101934_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116722","article-title":"Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents: a retrospective study of 240 patients","volume":"170","author":"Coropciuc","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2026.101934_bb0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcms.2020.01.014","article-title":"Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review","volume":"48","author":"Fortunato","year":"2020","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.bonr.2026.101934_bb0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bonr.2026.101934_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115676","article-title":"Adjuvant therapies for MRONJ: a systematic review","volume":"141","author":"Govaerts","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2026.101934_bb0045","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.clgc.2018.08.006","article-title":"Denosumab toxicity when combined with antiangiogenic therapies in patients with metastatic renal cell carcinoma: a GETUG study","volume":"17","author":"Guillot","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bonr.2026.101934_bb0050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jjco\/hyaa158","article-title":"A phase 2 study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma","volume":"51","author":"Harada","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2026.101934_bb0055","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer, excluding breast and prostate cancer, or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2026.101934_bb0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","article-title":"Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw","volume":"125","author":"Higuchi","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.bonr.2026.101934_bb0065","article-title":"Antiangiogenic medications impede the oral mucosal microcirculation and interfere with oral wound healing: a complication deserving of attention","volume":"6","author":"Huang","year":"2025","journal-title":"MedComm (2020)."},{"key":"10.1016\/j.bonr.2026.101934_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101934_bb0075","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws in cancer patients treated with denosumab versus zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"10.1016\/j.bonr.2026.101934_bb0080","doi-asserted-by":"crossref","first-page":"6397S","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2026.101934_bb0085","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomized, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bonr.2026.101934_bb0090","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","article-title":"Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib","volume":"48","author":"Mauceri","year":"2019","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bonr.2026.101934_bb0095","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bonr.2026.101934_bb0100","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101934_bb0105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101934_bb0110","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase 3 study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2026.101934_bb0115","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101934_bb0120","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws: 2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bonr.2026.101934_bb0125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","article-title":"Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers","volume":"96","author":"Saad","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.bonr.2026.101934_bb0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bonr.2026.101934_bb0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.36401\/JIPO-21-14","article-title":"Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis","volume":"4","author":"Srivastava","year":"2021","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.bonr.2026.101934_bb0140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/03008916251363754","article-title":"Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs \u00b1 IO and bone agents: a real-world analysis","volume":"111","author":"Stellato","year":"2025","journal-title":"Tumori"},{"key":"10.1016\/j.bonr.2026.101934_bb0145","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open-label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bonr.2026.101934_bb0150","first-page":"869","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"Van Cann","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bonr.2026.101934_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2022.12.028","article-title":"Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: results of the GETUG-AFU26-NIVOREN multicentre phase 2 study","volume":"182","author":"Velev","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bonr.2026.101934_bb0160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12903-023-03034-7","article-title":"Antiangiogenic drug aggravates the degree of antiresorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Oral Health"},{"key":"10.1016\/j.bonr.2026.101934_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2026.117795","article-title":"Combined antiresorptive and antiangiogenic therapy versus antiresorptive monotherapy: impact on the surgical prognosis of MRONJ patients with advanced malignancies","volume":"205","author":"Zou","year":"2026","journal-title":"Bone"}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:39:48Z","timestamp":1789544388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187226000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S2352187226000380"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101934","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101934"}}